Cellectar Biosciences, Inc. CLRB PHARMA
Company Overview
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR 121125, an iodine-125 Auger-emitting radioconjugate program; and CLR 225, an actinium-225 based radioconjugate program. The company has collaborative with Orano Med to develop alpha emitter lead-212 conjugated to phospholipid ether series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.05.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -45.48% |
| 6 Months: | -12.36% |
| 3 Months: | -3.98% |
| 1 Month: | -6.23% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)40.26 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 60.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CLRB Cellectar Biosciences, Inc. PHARMA | 2.41 | -1.09 | $22.78M | 0.00% | - | -119.57% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2013 | Jun 2013 | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -2.71M | -2.72M | -2.91M | -2.82M | -2.55M | -2.27M | -2.59M | -2.29M | -2.09M | -2.00M | -2.33M | -2.47M | -2.81M | -3.22M | -3.48M | -3.45M | -2.90M | -3.09M | -3.63M | -3.20M | -3.96M | -3.96M | -3.62M | -3.91M | -6.36M | -6.03M | -5.82M | -6.14M | -7.44M | -7.82M | -8.71M | -8.29M | -9.41M | -12.00M | -13.70M | -13.33M | -6.40M | -6.04M | -4.85M | -5.79M |
| Net Income | -3.45M | -2.06M | -1.32M | -2.94M | -2.09M | 324.02K | -2.30M | -2.29M | -1.86M | 824.56K | -2.13M | -2.29M | -2.89M | -3.12M | -3.47M | -3.48M | -2.92M | -3.01M | -3.62M | -3.19M | -3.90M | -3.96M | -3.61M | -3.91M | -6.36M | -6.03M | -5.82M | -6.14M | -7.44M | -7.81M | -7.19M | -10.18M | -17.52M | -26.64M | -919.37K | -14.66M | -6.60M | -5.45M | -4.44M | -5.65M |
| Diluted EPS | - | - | - | - | - | - | -3.04 | - | - | 0.91 | - | - | -0.24 | - | - | - | - | - | - | - | - | - | - | -0.15 | -0.13 | -1.14 | -0.97 | -1.00 | -1.22 | -1.28 | -0.76 | -0.90 | -1.55 | -0.91 | -5.43 | -12.13 | -4.30 | -3.39 | -1.41 | -1.33 |
| R&D Expense | 1.59M | 1.65M | 2.07M | 1.72M | 1.38M | 1.47M | 1.64M | 1.38M | 1.17M | 1.04M | 965.18K | 1.31M | 1.86M | 2.18M | 2.33M | 2.12M | 1.72M | 2.00M | 2.31M | 1.81M | 2.70M | 2.62M | 2.47M | 2.68M | 4.63M | 4.63M | 3.94M | 3.89M | 4.50M | 5.38M | 6.65M | 6.14M | 7.03M | 7.09M | 7.35M | 5.49M | 3.43M | 2.39M | 2.52M | 3.01M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2003 | Dec 2004 | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | - | - | - | - | - | - | - | -4.19M | -7.04M | -8.75M | -12.40M | -9.89M | -8.76M | -9.45M | -13.60M | -13.33M | -14.18M | -15.29M | -24.13M | -28.81M | -38.96M | -51.78M | -22.98M |
| Net Income | -295.79K | -342.76K | -481.84K | -963.44K | -5.09M | -6.09M | -6.22M | -4.56M | -7.44M | -8.80M | -10.78M | -8.05M | -5.50M | -6.18M | -13.56M | -13.24M | -14.09M | -15.09M | -24.12M | -28.60M | -42.77M | -44.58M | -21.79M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.84 | -4.35 | -4.05 | -3.50 | -41.89 | -8.35 |
| R&D Expense | - | - | - | - | - | - | - | 2.98M | 3.60M | 5.12M | 6.86M | 5.96M | 5.16M | 4.75M | 9.47M | 6.84M | 9.00M | 10.14M | 17.59M | 19.22M | 27.27M | 26.14M | 11.50M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Nov 2002 | Dec 2002 | Dec 2003 | Dec 2004 | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | - | - | - | - | - | - | 4.80M | 10.56M | 11.48M | 6.82M | 13.42M | 7.60M | 15.32M | 12.87M | 15.05M | 12.25M | 58.66M | 37.20M | 21.59M | 12.08M | 25.47M | 14.98M |
| Total Equity | 0 | 599.38K | 388.94K | 46.17K | 400.21K | 6.55M | 2.53M | 9.84M | 4.13M | 133.76K | 9.48M | 10.16M | 1.70M | 6.70M | 1.65M | 13.54M | 10.75M | 13.26M | 9.06M | 54.79M | 33.05M | 8.15M | -15.16M | 14.29M | 8.54M |
| Cash & Equivalents | 0 | - | - | - | - | - | - | - | 980.12K | 673.74K | 5.51M | 4.68M | 2.42M | 9.42M | 3.91M | 11.44M | 10.01M | 13.26M | 10.61M | 57.17M | 35.70M | 19.87M | 9.56M | 23.29M | 13.20M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | 450.00K | 450.00K | 450.00K | 330.22K | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - | - | 1.32M | 5.12M | 6.72M | 5.95M | 1.78M | 2.12M | 1.79M | 3.19M | 3.86M | 4.16M | 6.08M | 25.85M | 9.80M | 5.06M |
| Current Liabilities | - | - | - | - | - | - | - | - | - | 904.82K | 503.58K | 732.69K | 4.52M | 6.23M | 5.70M | 1.63M | 2.11M | 1.62M | 2.77M | 3.56M | 3.99M | 5.53M | 25.36M | 9.39M | 4.75M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -3.38M | -5.97M | -6.59M | - | - | - | -8.28M | -11.02M | -11.44M | -11.69M | -13.93M | -22.57M | -25.22M | -32.38M | -47.58M | -23.12M |
| Investing Cash Flow | -1.65K | 1.29M | -2.10M | - | - | - | -72.25K | -346.70K | -329.99K | -24.54K | -62.35K | -141.36K | -225.97K | -864.04K | -104.19K | -5.88K |
| Financing Cash Flow | 3.08M | 9.52M | 7.85M | - | - | - | 15.94M | 9.93M | 15.02M | 9.02M | 60.55M | 1.25M | 9.61M | 22.94M | 61.41M | 13.03M |
| Capital Expenditure | -1.65K | -118.41K | -97.69K | -147.81K | -29.57K | -58.47K | -72.25K | -346.70K | -384.99K | -24.54K | -62.35K | -141.36K | -225.97K | -864.04K | -104.19K | -5.88K |
| Free Cash Flow | -3.38M | -6.09M | -6.68M | - | - | - | -8.35M | -11.37M | -11.83M | -11.72M | -14.00M | -22.71M | -25.45M | -33.24M | -47.69M | -23.12M |
| Share Buybacks | - | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2003 | Dec 2004 | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| ROE % | -76.1% | -742.3% | -120.4% | -14.7% | -201.5% | -61.9% | -150.7% | -3,409.2% | -78.4% | -86.6% | -634.4% | -120.2% | -333.1% | -45.6% | -126.1% | -99.8% | -155.6% | -27.5% | -73.0% | -350.8% | 282.1% | -311.9% | -255.2% |
| ROCE % | - | - | - | - | - | - | - | -107.6% | -70.0% | -81.5% | -540.9% | -137.6% | -462.6% | -69.0% | -126.4% | -99.2% | -149.5% | -27.8% | -72.7% | -179.4% | 293.3% | -321.9% | -224.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Caligan Partners, LP | 4.97% | 470.00K | $1.12M |
| 2 | Stempoint Capital LP | 3.76% | 354.94K | $844.75K |
| 3 | Vanguard Capital Management LLC | 3.46% | 327.37K | $779.13K |
| 4 | SilverArc Capital Management, LLC | 3.40% | 321.73K | $765.71K |
| 5 | Bleichroeder LP | 3.05% | 288.68K | $687.06K |
| 6 | Jupiter Topco LLC | 2.90% | 274.16K | $652.49K |
| 7 | Balyasny Asset Management LP | 2.33% | 220.00K | $523.60K |
| 8 | Nantahala Capital Management, LLC | 2.33% | 220.00K | $523.60K |
| 9 | Empery Asset Management, LP | 2.01% | 189.60K | $451.26K |
| 10 | Diadema Partners LP | 1.46% | 138.34K | $329.25K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CLRB
Cellectar Biosciences (CLRB) Stock Fair Value Moves Lower As Analysts Weigh Execution Risk - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxONHZfMzRVZld5aTlQbl9UV2ZZUjNtckx2YzlCNUstLTV2ZkJfNkRkQVlLODBDVGdvYVNkaEtWOGJfbHFPVFIyak4wYVhTUENtM3owNmxiNldfR1ZjRmJLcll1T2hNT2Itd0pCRVhJZlhSaG5nUGlDWng5dlJTWXk4X1Bad0llb3FfVnNIMH…
CLRB Stock Surged 27% Today – Here’s Why Retail Is Bullish About Cellectar’s Blood Cancer Trial Data - Stocktwits
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxNdEhZWmxKUEx4TTVZSkU0bTlIVnN1bWJTT0p1WHhPOGMwRmhGYVpUMlpXVkI0Y25kYlQyQ3RXZ3RVRXpPbU9LNHZXWEVmM09jUVR0YlRGcy1kSVY1TlVUZ0JWNU8yZkg3OXJ6aVJjSl9Mb0ZNTkVSUUpNOXU0aUNFN2hNVVVIMkUweFBQSU…
CLRB Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9ObTZRSWlrYUNyc2JqTTJjNWNWUG9tYzVDVFRHbU1EQmxNZzdSX2J0Tm1fb2hHeEEzdkV3QWNFTmlpYjN0WVJJcE5PNURBajJoZmRjWlRKWTVhSjlvZUtzSmdSaEpGWjFXVHM5Z2JYWlEwbHBfSDdTSk9R?oc=5" target="_blank">CLR…
Cellectar Myeloma Data: 84.6% of 26 Evaluable Patients Stable or Better - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxPb3NXYThQTnY4dHRjQ3hNZG1YUG8tMW12N3FKak5Bd0R6Tnp1WndBZnhoMXh4Y2FNOThRS05aTXlXMy1KUFlBMlpYMXQ0ZjNLV184cTNrR29PVU1qSkJOcW9GcTZxZnY1MjNhS1gtLW16N3ZBU21WSXpqNnBJeFhLVW1DcFV4N0VTZGlyWG…
Should I buy Cellectar Biosciences (CLRB) - Zacks Investment Research
<a href="https://news.google.com/rss/articles/CBMibEFVX3lxTE5TU01Fb3g5VXozNnRuU3h5RDItcl9VeTg5OUVvVTRQYmxKSkJPS21TZDhfVDBOQmg5RTdpdmp5TTNKZjBGRFpQSW9heGtkYmRqUlE4dlZPZlpTeHR1X2Z2a2liRk1oMmdCM1JEZQ?oc=5" target="_blank">Should I buy Cellecta…
CLRB - Cellectar Biosciences Inc Stock Price and Quote - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE1tSUlBZTdHSGEtUjFnbEZPX3NqNEk0MVNUQ2dlLS1fN1ZGa0swMlBZRXFndk5kLTRTajdyMDVCd0dCM0VISWc?oc=5" target="_blank">CLRB - Cellectar Biosciences Inc Stock Price and Quote</a> <f…
CLRB — Frequently Asked Questions
What is the current share price of Cellectar Biosciences, Inc. (CLRB)?
As of 2026-09-19 21:16 PDT, Cellectar Biosciences, Inc. (CLRB) trades at $2.41 on NasdaqCM. Its 52-week range is $2.23 to $6.17.
What is the market capitalisation of CLRB?
Cellectar Biosciences, Inc. (CLRB) has a market capitalisation of $22.78M on NasdaqCM.
What is the P/E ratio of CLRB?
CLRB trades at a trailing price-to-earnings (P/E) ratio of -1.09. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.65.
What is the return on equity (ROE) of CLRB?
CLRB has a return on equity (ROE) of -119.57%.
Is CLRB a good stock to buy?
This page provides a data-driven analysis of Cellectar Biosciences, Inc. (CLRB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.